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Background
The number of people infected due to intravenous drug
use remains at a level of 50% so far, despite the HIV sexual
transmission rate increasing. Chronic hepatitis C (HCV)
infection is currently one of the most clinically relevant
co-morbidities (>80%) in the population of HIV-positive
drug-users. Due to the wide use of HAART and prevention
of opportunistic diseases, life expectancy of HIV-infected
individuals has increased and chronic viral hepatitis has
become one of the principal causes of death side-by-side
with tuberculosis. We started HCV treatment in 2007.
Prior to treatment, all HCV co-infected patients required
an HCV genotype testing.
Methods
The HCV genotypes distribution in the HIV-infected resi-
dents of the Nizhny Novgorod area was studied. We inves-
tigated the 366 blood samples taken from 366 patients by
polymerase chain reaction method (PCR) using the
"AmpliSens-50-R" test-system and the Bio-Rad MyCycler
Sample Loading Tray.
Summary of results
HCV genotype 3a predominated in our cohort samples
(43.9%) and the remainders were type 1b (33.6%) and
type 1a and 2 with low distribution (5.5% and 3.3%,
respectively). In 20 samples we have found mixed 1b+3a
genotypes; in 30 cases genotypes were not detected.
Conclusion
In the Nizhny Novgorod area, a distribution of HCV gen-
otypes among HIV-infected individuals was observed
with a higher prevalence of genotype 3a (43.9%) by com-
parison with the population of Russia (10.5%). As has
been shown in previous research, HCV genotype 3a is a
favorable prognostic factor for achieving in most cases a
sustained virologic response. Our findings have potential
implications for appropriate patient selection for HCV
treatment, as individuals carrying this genotype are more
likely to respond to therapy.
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